GlassScriptPhysician profile
Elias Akl
NPI 1104176106
$79,723.16
in general payments reported to CMS, 2019-2025
29 companies · $35K in 2025
The $35K reported for 2025 was more than what 94% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $793 · 2021: $1,038 · 2022: $1,917 · 2023: $5,500 · 2024: $35K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Food and Beverage: $10K · Travel and Lodging: $4,913 · Consulting Fee: $1,670 · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,635.00 |
| Food and Beverage | $10,304.28 |
| Travel and Lodging | $4,912.61 |
| Consulting Fee | $1,670.00 |
| Education | $243.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $66,902.76 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Pfizer INC. | $2,891.95 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,960.72 | 2020-2025 | Trelegy Ellipta, Nucala |
| Genzyme Corporation | $1,931.78 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,566.43 | 2020-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $673.76 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Genentech USA, INC. | $560.41 | 2020-2025 | Xolair |
| Csl Behring | $506.82 | 2021-2025 | Hizentra, Haegarda, Andembry |
| Amgen INC. | $492.92 | 2021-2025 | Tezspire |
| Optinose US, INC. | $433.68 | 2020-2025 | |
| Aimmune Therapeutics, INC. | $299.48 | 2020-2022 | |
| Grifols USA, LLC | $225.75 | 2020-2025 | Xembify |
| Kaleo, INC. | $213.38 | 2020-2024 | Auvi-Q |
| Alk-Abello, INC | $208.09 | 2020-2022 | |
| Blueprint Medicines Corporation | $147.63 | 2023 | Ayvakit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $125.61 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $120.45 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $68.38 | 2020-2023 | Airduo Digihaler |
| Novartis Pharmaceuticals Corporation | $63.13 | 2020-2025 | |
| Biocryst US Sales Co., LLC | $60.03 | 2021 | |
| Sanofi-Aventis U.S. LLC | $59.99 | 2022 | |
| Organon LLC | $42.36 | 2025 | Vtama |
| Inspire Medical Systems, INC. | $37.23 | 2023 | Inspire |
| Lilly USA, LLC | $25.74 | 2024 | Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.41 | 2020-2021 | |
| Greer Laboratories, INC. | $25.18 | 2025 | Oralair |
| Medtronic, INC. | $21.15 | 2025 | Propel |
| Octapharma USA, INC. | $20.42 | 2020 | |
| Bio Products Laboratory USA, INC. | $12.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elias Akl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.